helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2025-18-3-113-120helmholtzeyeinstitute-1887Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУFOR OPHTHALMOLOGY PRACTITIONERSКомбинированная терапия пролиферативной диабетической ретинопатии с применением российского биоаналога ранибизумабаCombination therapy of proliferative diabetic retinopathy using the Russian biosimilar ranibizumabhttps://orcid.org/0000-0002-0181-9873МалаховаА. И.MalakhovaA. I.

Анна Ивановна Малахова — канд. мед. наук, врач-офтальмолог

пр-т Гагарина, д. 27, Смоленск, 214018

Anna I. Malakhova — Cand. of Med. Sci., ophthalmologist

27, Gagarina Aven, Smolensk, 214018

gloft67@mail.ruhttps://orcid.org/0000-0002-5478-6040БыстревскаяА. А.BystrevskayaA. A.

Анна Анатольевна Быстревская — канд. мед. наук, доцент кафедры глазных болезней

ул. Крупской, д. 28, Смоленск, 214019

Anna A. Bystrevskaya — Cand. of Med. Sci., associate professor, chair of eye diseases

28, Krupskaya St., Smolensk, 214019

ОГБУЗ «Смоленская областная клиническая больница»РоссияSmolensk Regional Clinical HospitalRussian FederationФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава РоссииРоссияSmolensk State Medical UniversityRussian Federation202517092025183113120Copyright © Малахова А.И., Быстревская А.А., 20252025Малахова А.И., Быстревская А.А.Malakhova A.I., Bystrevskaya A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/1887

Пролиферативная диабетическая ретинопатия (ПДР) является одной из ведущих причин потери зрения при сахарном диабете. Панретинальная лазерная коагуляция сетчатки (ПРЛК) входит в перечень основных способов лечения пролиферативного процесса при диабетическом поражении сетчатки. В проспективном рандомизированном многоцентровом открытом исследовании PROTEUS в 2018 г. была доказана более высокая эффективность ПРЛК в сочетании с интравитреальным введением ранибизумаба по сравнению с одной только ПРЛК при лечении пациентов с ПДР высокого риска. В данной статье приведены три клинических случая комбинированной терапии ПДР с применением российского биоаналога ранибизумаба у пациентов с сахарным диабетом I типа.

Proliferative diabetic retinopathy (PDR) is one of the main causes of vision loss in diabetes mellitus. Panretinal laser photocoagulation (PRP) remains one of the main methods of treating the proliferative process in diabetic retinal damage. In 2018, a prospective randomized multicenter open-label PROTEUS study demonstrated higher efficacy of PRP in combination with intravitreal ranibizumab compared to PRP alone in the treatment of patients with high-risk PDR. This article presents three clinical cases of combination therapy for proliferative diabetic retinopathy using a Russian biosimilar of ranibizumab in patients with type 1 diabetes mellitus.

пролиферативная диабетическая ретинопатияпанретинальная лазерная коагуляцияранибизумабинтравитреальные инъекцииproliferative diabetic retinopathypanretinal laser coagulationranibizumabintravitreal injectionReferencesFlaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020; 127 (1): P66–P145. doi: 10.1016/j.ophtha.2019.09.025Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020; 127 (1): P66–P145. doi: 10.1016/j.ophtha.2019.09.025Нероев В.В., Зайцева О.В., Михайлова Л.А. Распространенность диабетической ретинопатии в Российской Федерации по данным федеральной статистики. Российский офтальмологический журнал. 2023; 16 (3): 7–11. https://doi.org/10.21516/2072-0076-2023-16-3-7-11Neroev V.V., Zaitseva O.V., Mikhailova L.A. Prevalence of diabetic retinopathy in the Russian Federation according to federal statistics. Russian ophthalmological journal. 2023; 16 (3): 7–11 (In Russ.). https://doi.org/10.21516/2072-0076-2023-16-3-7-11Нероев В.В. Диагностика и лечение диабетической ретинопатии и диабетического макулярного отека. Российский офтальмологический журнал. 2014; 7 (3): 71–84.Neroev V.V. Diagnostics and treatment of diabetic retinopathy and diabetic macular edema. Russian ophthalmological journal. 2014; 7 (3): 71–84 (In Russ.).Williams R, Airey M, Baxter H, et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004; 18 (10): 963–83. doi: 10.1038/sj.eye.6701476Williams R, Airey M, Baxter H, et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004; 18 (10): 963–83. doi: 10.1038/sj.eye.6701476Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019 Feb; 7 (2): 140–9. doi: 10.1016/S2213-8587(18)30128-1Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019 Feb; 7 (2): 140–9. doi: 10.1016/S2213-8587(18)30128-1Le NT, Kroeger ZA, Lin WV, Khanani AM, Weng CY. Novel treatments for diabetic macular edema and proliferative diabetic retinopathy. Curr Diab Rep. 2021; 21 (10): 43. doi: 10.1007/s11892-021-01412-5Le NT, Kroeger ZA, Lin WV, Khanani AM, Weng CY. Novel treatments for diabetic macular edema and proliferative diabetic retinopathy. Curr Diab Rep. 2021; 21 (10): 43. doi: 10.1007/s11892-021-01412-5Crabtree GS, Chang JS. Management of complications and vision loss from proliferative diabetic retinopathy. Curr Diab Rep. 2021; 21 (9): 33. doi: 10.1007/s11892-021-01396-2Crabtree GS, Chang JS. Management of complications and vision loss from proliferative diabetic retinopathy. Curr Diab Rep. 2021; 21 (9): 33. doi: 10.1007/s11892-021-01396-2Demir G, Arici M, Alkin Z. Preoperative evaluation of tractional retinal detachment with b-mode ultrasonography in diabetic vitreous hemorrhage. Beyoglu Eye J. 2021; 6 (1): 49–53. doi: 10.14744/bej.2021.58561Demir G, Arici M, Alkin Z. Preoperative evaluation of tractional retinal detachment with b-mode ultrasonography in diabetic vitreous hemorrhage. Beyoglu Eye J. 2021; 6 (1): 49–53. doi: 10.14744/bej.2021.58561Wang Q, Zhao J, Xu Q, et al. Visual outcomes and complications following one-way air-fluid exchange technique for vitreous hemorrhage post vitrectomy in proliferative diabetic retinopathy patients. BMC Ophthalmol. 2021; 21 (1): 129. doi: 10.1186/s12886-021-01885-8Wang Q, Zhao J, Xu Q, et al. Visual outcomes and complications following one-way air-fluid exchange technique for vitreous hemorrhage post vitrectomy in proliferative diabetic retinopathy patients. BMC Ophthalmol. 2021; 21 (1): 129. doi: 10.1186/s12886-021-01885-8Figueira J, Fletcher E, Massin P, et al; EVICR.net Study Group. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study). Ophthalmology. 2018; 125 (5): 691–700. doi: 10.1016/j.ophtha.2017.12.008Figueira J, Fletcher E, Massin P, et al; EVICR.net Study Group. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study). Ophthalmology. 2018; 125 (5): 691–700. doi: 10.1016/j.ophtha.2017.12.008Bhatwadekar AD, Shughoury A, Belamkar A, Ciulla TA. Genetics of diabetic retinopathy, a leading cause of irreversible blindness in the industrialized world. Genes (Basel). 2021; 12 (8): 1200. doi: 10.3390/genes12081200Bhatwadekar AD, Shughoury A, Belamkar A, Ciulla TA. Genetics of diabetic retinopathy, a leading cause of irreversible blindness in the industrialized world. Genes (Basel). 2021; 12 (8): 1200. doi: 10.3390/genes12081200Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020; 37: 101799. doi: 10.1016/j.redox.2020.101799Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020; 37: 101799. doi: 10.1016/j.redox.2020.101799Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020; 34 (Suppl 1): 1–51. doi: 10.1038/s41433-020-0961-6Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020; 34 (Suppl 1): 1–51. doi: 10.1038/s41433-020-0961-6Нероев В.В., Зайцева О.В., Балацкая Н.В., Лазутова А.А. Локальная и системная продукция цитокинов при осложненной пролиферативной диабетической ретинопатии. Медицинская иммунология. 2020; 22 (2): 301–10. https://doi.org/10.15789/1563-0625-LAS-1802Neroev V.V., Zaytseva O.V., Balatskaya N.V., Lazutova A.A. Local and systemic production of 45 cytokines in complicated proliferative diabetic retinopaty. Medical immunology (Russia). 2020; 22 (2): 301–10 (In Russ.). https://doi.org/10.15789/1563-0625-LAS-1802Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004 Aug; 25 (4): 581–611. doi: 10.1210/er.2003-0027Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004 Aug; 25 (4): 581–611. doi: 10.1210/er.2003-0027Липатов Д.В., Смирнова Н.Б., Александрова В.К. Современный алгоритм лазерной коагуляции сетчатки при диабетической ретинопатии. Сахарный диабет. 2007; 10 (3): 45–6. https://doi.org/10.14341/2072-0351-5997Lipatov D.V., Smirnova N.B., Aleksandrova V.K. Modern algorithm of laser coagulation of the retina in diabetic retinopathy. Sakharnyy diabet. 2007; 10 (3): 45–6 (In Russ.). https://doi.org/10.14341/2072-0351-5997Клинические рекомендации. Сахарный диабет: ретинопатия диабетическая, макулярный отек диабетический. Минздрав России. 2023. Ссылка активна на 07.05.2025. https://cr.minzdrav.gov.ru/view-cr/115_2Clinical guidelines. Diabetes mellitus: diabetic retinopathy, diabetic macular edema. Ministry of Health of the Russian Federation. 2023. Accessed 07.05.2025 (In Russ.). https://cr.minzdrav.gov.ru/view-cr/115_2Macaron MM, Al Sabbakh N, Shami MZ, et al. Anti-VEGF injections vs. panretinal photocoagulation laser therapy for proliferative diabetic retinopathy: A systematic review and meta-analysis. Ophthalmol Retina. 2025; 9 (2): 105–21. doi: 10.1016/j.oret.2024.08.004Macaron MM, Al Sabbakh N, Shami MZ, et al. Anti-VEGF injections vs. panretinal photocoagulation laser therapy for proliferative diabetic retinopathy: A systematic review and meta-analysis. Ophthalmol Retina. 2025; 9 (2): 105–21. doi: 10.1016/j.oret.2024.08.004Zhang W, Geng J, Sang A. Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment against PRP alone for diabetic retinopathy: A systematic review with meta-analysis. Front Endocrinol (Lausanne). 2022; 13: 807687. doi: 10.3389/fendo.2022.807687Zhang W, Geng J, Sang A. Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment against PRP alone for diabetic retinopathy: A systematic review with meta-analysis. Front Endocrinol (Lausanne). 2022; 13: 807687. doi: 10.3389/fendo.2022.807687Yin H, Zhong S. Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study. Medicine (Baltimore). 2023; 102 (31): e34170. doi: 10.1097/MD.0000000000034170Yin H, Zhong S. Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study. Medicine (Baltimore). 2023; 102 (31): e34170. doi: 10.1097/MD.0000000000034170Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous Ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. AMA. 2015; 314 (20): 2137–46. doi: 10.1001/jama.2015.15217. Erratum in: JAMA. 2016 Mar 1;315(9):944. doi: 10.1001/jama.2016.1591Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous Ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. AMA. 2015; 314 (20): 2137–46. doi: 10.1001/jama.2015.15217. Erratum in: JAMA. 2016 Mar 1;315(9):944. doi: 10.1001/jama.2016.1591Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015; 122 (2): 367–74. doi: 10.1016/j.ophtha.2014.08.048Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015; 122 (2): 367–74. doi: 10.1016/j.ophtha.2014.08.048Sadiq MA, Hassan M, Soliman MK, et al. Effects of two different doses of ranibizumab on diabetic retinopathy severity. Ophthalmol Retina. 2017 Nov-Dec; 1 (6): 566–7. doi: 10.1016/j.oret.2017.03.002Sadiq MA, Hassan M, Soliman MK, et al. Effects of two different doses of ranibizumab on diabetic retinopathy severity. Ophthalmol Retina. 2017 Nov-Dec; 1 (6): 566–7. doi: 10.1016/j.oret.2017.03.002Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018; 136 (10): 1138–48. doi: 10.1001/jamaophthalmol.2018.3255Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018; 136 (10): 1138–48. doi: 10.1001/jamaophthalmol.2018.3255Fragiotta S, Bassis L, Abdolrahimzadeh B, et al. Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents. Int J Mol. Sci. 2024; 25 (8): 4433. https://doi.org/10.3390/ijms25084433Fragiotta S, Bassis L, Abdolrahimzadeh B, et al. Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents. Int J Mol. Sci. 2024; 25 (8): 4433. https://doi.org/10.3390/ijms25084433Воскресенская А.А., Саркизова М.Б., Ходжаев Н.С. и др. Биоаналоги ранибизумаба при заболеваниях сетчатки: новые возможности в офтальмологии. Вестник офтальмологии. 2025; 141 (2): 106–16. https://doi.org/10.17116/oftalma2025141021106Voskresenskaya A.A., Sarkizova M.B., Khodzhaev N.S., et al. Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology. Russian annals of ophthalmology. 2025; 141 (2): 106–16 (In Russ.). https://doi.org/10.17116/oftalma2025141021106Иванов Р., Секарёва Г., Кравцова О. и др. Правила проведения исследований биоаналоговых лекарственных средств (биоаналогов). Фармакокинетика и фармакодинамика. 2014; 1: 21–36.Ivanov R., Sekareva G., Kravtsova O., et al. Rules for conducting studies of biosimilar drugs (bioanalogues). Farmakokinetika i farmakodinamika. 2014; 1: 21–36 (In Russ.).Государственный реестр лекарственных средств. Инструкция по применению препарата Лаксолан. Ссылка активна на 11.06.2025. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2d1ada9-4b0f-4f8d-b3e0-88a50c6d12e6ГState Register of Medicines. Instructions for use of the drug Laxolan. Link active as of 11.06.2025. Accessed 16.12.2024 (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2d1ada9-4b0f-4f8d-b3e0-88a50c6d12e6Шадричев Ф.Е., Демидова Т.Ю., Григорьева Н.Н., Кожевников А.А. Профилактика слепоты при сахарном диабете. От лазерной коагуляции сетчатки к фармакологии. Фарматека. 2019; 26 (4): 68–78. https://dx.doi.org/10.18565/pharmateca.2019.4.68-78Shadrichev F.E., Demidova T.Yu., Grigorieva N.N., Kozhevnikov A.A. Prevention of blindness in diabetes mellitus. From laser coagulation of the retina to pharmacology. Farmateka. 2019; 26 (4): 68–78 (In Russ.). https://dx.doi.org/10.18565/pharmateca.2019.4.68-78Шадричев Ф.Е. Протокол офтальмологического ведения больных сахарным диабетом. Офтальмологические ведомости. 2008; 1 (2): 54–61.Shadrichev F.E. Protocol of ophthalmological management of patients with diabetes mellitus. Oftal’mologicheskiye vedomosti. 2008; 1 (2): 54–61 (In Russ.).International Council of Ophthalmology (ICO). ICO Guidelines for Diabetic Eye Care. Int Counc Ophthalmol. 2017. https://vrsp.org.ph/wp-content/uploads/2018/08/ICOGuidelinesforDiabeticEyeCare.pdfInternational Council of Ophthalmology (ICO). ICO Guidelines for Diabetic Eye Care. Int Counc Ophthalmol. 2017. https://vrsp.org.ph/wp-content/uploads/2018/08/ICOGuidelinesforDiabeticEyeCare.pdfXiao A, Zhou Q, Shao Y, Zhong HF. Effect of intravitreal injection of ranibizumab on retinal ganglion cells and microvessels in the early stage of diabetic retinopathy in rats with streptozotocin-induced diabetes. Exp Ther Med. 2017 Jun; 13 (6): 3360–8. doi: 10.3892/etm.2017.4431Xiao A, Zhou Q, Shao Y, Zhong HF. Effect of intravitreal injection of ranibizumab on retinal ganglion cells and microvessels in the early stage of diabetic retinopathy in rats with streptozotocin-induced diabetes. Exp Ther Med. 2017 Jun; 13 (6): 3360–8. doi: 10.3892/etm.2017.4431Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A position statement by the American Diabetes Association. Diabetes Care. 2017 Mar; 40 (3): 412–8. doi: 10.2337/dc16-2641Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A position statement by the American Diabetes Association. Diabetes Care. 2017 Mar; 40 (3): 412–8. doi: 10.2337/dc16-2641

The authors declare that there are no conflicts of interest present.